Study on the efficacy and safety of reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy

Study on the efficacy and safety of reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy - Reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008819

Enrollment

Registered

2012-11-01

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic central serous chorioretinopathy

Interventions

6mg/m2 intravenous infusion of verteporfin followed by delivery of laser 15 minutes after the start of the infusion. Light dose rate is 300mW/cm2, time of photosensitization is 83 seconds, and total l

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 3 months or more after onset 2) presence of angiographic leakage under fovea in fluorescein angiography 3) presence of serous detachment on optical coherence tomography 4) obtain written informed consent

Exclusion criteria

Exclusion criteria: 1) drug allergy to verteporfin 2) porphyria, or hypersensitivity to artificial illumination 3) macular diseases other than central serous chorioretinopathy 4) pregnant or expecting pregnancy 5) others, inappropriate case judged by investigator or subinvestigators

Design outcomes

Primary

Measure	Time frame
resolution of serous retinal detachment of 7 days, 1 month, 3 months, 6 months and 1 year after reduced-fluence photodynamic therapy	—

Secondary

Measure	Time frame
1) visual acuity 2) optical coherence tomography 3) fluorescein angiography 4) indocyanine green angiography evaluation time 1), 2): 7 days, 1 month, 3 months, 6 months, 1 year after RF-PDT 3), 4): 1 month, 3 months, 1 year after RF-PDT	—

Countries

Japan

Contacts

Public ContactKenichi Mizukawa

Kawasaki Medical School Hospital Ophthalmology

kmsrec@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026